Navigation Links
Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
Date:4/23/2009

LAIYANG, China, April 23 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has changed its name to "Jiangbo Pharmaceuticals, Inc." ("Jiangbo").

The Company received confirmation from the Department of State of the State of Florida that the Certificate of Amendment to the Company's Amended and Restated Articles of Incorporation to effect a change of its name was filed. The Board of Directors of the Company as well as the holders of a majority of the outstanding shares of the Company's voting stock approved the name change by written consent. The Company will soon receive a new CUSIP number for its common stock, after which a new ticker symbol for the Company's shares will be assigned by the OTCBB. The Company will announce its new ticker symbol and CUSIP number as soon as it receives them.

The Company's wholly owned operating subsidiary Laiyang Jiangbo Pharmaceutical Co., Ltd., a PRC company, markets the Company's products throughout China under the brand name "Jiangbo." Part of the Company's branding strategy includes using similar packaging for its products and creating a product line of drugs which are widely known by Jiangbo's brand name and logo.

"We support Jiangbo with the idea that 'We aim high, We aim wide.' It is part of our corporate culture to provide our customers with products that will help them lead happy and healthy lives. We always strive to produce the best possible quality products and ensure our reputation while we continue to grow our Company's revenues, profits and value," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo.

"We changed our corporate name to Jiangbo to align the name of our public company with the name of our products. With this change, we hope that our customers, partners and shareholders will view our products as synonymous with our Company. We want people to think of only 'Jiangbo' as we continue to improve our Company and expand our product line," concluded Mr. Cao.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:  http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
2. Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
3. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
4. New Directions in Angioedema: A Focus on Pathogenesis and Classification
5. Angiogenesis inhibitor improves brain tumor survival by reducing edema
6. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
7. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
8. Study sheds light on angiogenesis inhibitors, points to limitations, solutions
9. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
10. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
11. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... Christie Medical Holdings, Inc. presented the ... VeinViewer® Vision vein finder for the nursing school simulation lab. This ... draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful new ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a ... Providers list for its expertise in eClinical Solutions. DDi has built its solution ... technology needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. ... , As Winston Churchill said, “Those who don’t learn from history are doomed to repeat ... when they come knocking this year. But that takes time. , Take a close ...
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Eli Lilly and Company (NYSE: LLY ) today ... disodium) vitamin regimen patent would not presently be infringed by ... , Italy and ... with dextrose solution.  --> ... Appeal held that Lilly,s patent would be indirectly infringed by ...
(Date:2/12/2016)... 12 2016  OMS Supply, a large provider of ... announced today the recent launching of their new company ... of features that enhance the user experience and enable ... --> --> Despite ... company that started in early 2016, they have already ...
(Date:2/12/2016)... LOUISVILLE, Ky. , Feb. 12, 2016 ... it has completed a $47.1 million Series ... investors Cormorant Asset Management, Hillhouse Capital Group ... investors Morningside Venture Investments, AJU IB Investment, ... will be used to further advance clinical ...
Breaking Medicine Technology: